Dan Kidle

Dan identifies promising investment opportunities across Arboretum’s sectors of interest, with particular emphasis on life science tools. He also works closely with portfolio companies to support strategic decision-making, fundraising efforts, and financial analysis. Since joining Arboretum in 2011, Dan has undertaken primary due diligence responsibilities on more than a dozen of Arboretum’s new and follow-on investments including NeuMoDx, Rethink, Strata Oncology, and SI-BONE. Dan currently serves as a board director for Swift Biosciences, Dropworks, JUMPCODE Genomics and Flosonics Medical and previously for IntelliCyt, which was acquired in 2016. Dan was a recipient of the National Venture Capital Association’s Rising Star Award in 2020.

Prior to joining Arboretum, Dan was a Financial Analyst at Eli Lilly & Company, supporting the company’s U.S. sales and marketing operations. Dan currently serves on the Investment Advisory Board for the Michigan Biomedical Venture Fund at the University of Michigan.

Dan earned a BBA and an MBA from the Ross School of Business at the University of Michigan.